Skip to main content
GWGovwatch
CongressBillsCommitteesPresidentMoneyPulseMisconductElectionsMap
Donate

Weekly accountability digest

One email a week with new votes, moving bills, and misconduct updates. No spam.

GW

Govwatch. Public data about Congress, in one place, in plain English.

Built with public data. Not affiliated with the U.S. government.

Explore

  • Officials
  • Legislation
  • Committees
  • Congress Pulse
  • Trending Topics
  • Bipartisan Leaderboard
  • Weekly Digest
  • Misconduct
  • Predictions

Learn

  • How Congress Works
  • How a Bill Becomes Law
  • Campaign Finance 101
  • Glossary

Tools

  • My Representatives
  • Compare Members
  • Bill Watchlist
  • Search
  • District Map
  • Follow the Money
  • Watch Live

Site

  • About
  • Contact
  • Corrections
  • Privacy Policy
  • Terms of Service

Data Sources

Congress.gov API v3
Bills, members, votes
GovInfo API
Floor speeches, reports, bill text
Federal Election Commission (FEC)
Campaign finance
VoteView (UCLA)
Ideology scores (DW-NOMINATE)
GovTrack.us
Misconduct data (CC0)
U.S. Census Bureau
District demographics

Data Last Updated

Bills & Votes: 5 hours ago
Support This Project

This site is free. Donations help cover hosting, API fees, and keeping the data fresh.

All data is sourced from official government APIs and public records. This site is for informational purposes only.

© 2026 Govwatch

HR8667Referred to Committee

MISSION Rx Act

Share:
Introduced
In Committee
3
Passed One Chamber
4
Passed Both
5
Signed into Law
119th
Congress
2026-05-07
Introduced
14
Cosponsors
HR
ⓘ
Type

Sponsor

Eugene Simon Vindman
Eugene Simon Vindman
Democrat · VA · Representative
Votes with party: 90.5% (603 recorded votes)
Top industries funding sponsor:
  • Veterans$4,000k

Full profile: /officials/V000138

Source: Congress.gov · FEC

Cosponsors (14)

Members who have signed on to support this bill since introduction. Source: Congress.gov.

  • Chrissy Houlahan (D-PA-6)Original· 2026-05-07
  • Christopher R. Deluzio (D-PA-17)Original· 2026-05-07
  • Maggie Goodlander (D-NH-2)Original· 2026-05-07
  • Patrick Ryan (D-NY-18)Original· 2026-05-07
  • Seth Moulton (D-MA-6)Original· 2026-05-07
  • William R. Keating (D-MA-9)Original· 2026-05-07
  • Eleanor Holmes Norton (D-DC)· 2026-05-11
  • Melanie A. Stansbury (D-NM-1)· 2026-05-11
  • Mike Quigley (D-IL-5)· 2026-05-12
  • Ro Khanna (D-CA-17)· 2026-05-12
  • André Carson (D-IN-7)· 2026-05-13
  • Nikki Budzinski (D-IL-13)· 2026-05-13

Latest Action

The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →

Referred to the Committee on Veterans' Affairs, and in addition to the Committee on Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

2026-05-07

Source: Congress.gov

Committee Activity

Currently in

  • House Committee on Armed ServicesReferred To · 2026-05-07
  • House Committee on Veterans' AffairsReferred To · 2026-05-07

Previously

  • Armed Services CommitteeReferred To · 2026-05-07
  • Veterans' Affairs CommitteeReferred To · 2026-05-07

Plain-English Summary

This bill would cap how much military families and veterans have to pay out of pocket for certain prescription drugs covered by TRICARE (the military health insurance program) and VA benefits, and would also limit the prices the federal government pays for those same drugs. The goal is to make medications more affordable for active-duty service members, retirees, their families, and veterans while reducing what taxpayers spend on drug costs. The bill is currently being reviewed by committees in Congress that handle military and veterans' affairs.

AI-assisted summary generated from the official bill metadata (title, subjects, actions) sourced from Congress.gov. Cached and reviewed. Always verify against the official text linked below.

Subjects

Armed Forces and National Security

Full Bill Text

Verbatim text published on Congress.gov via GovInfo. Use Cmd+F / Ctrl+F to search within this excerpt.

[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H.R. 8667 Introduced in House (IH)] <DOC> 119th CONGRESS 2d Session H. R. 8667 To amend titles 10 and 38, United States Code, to set the maximum cost- sharing amount paid by an eligible covered beneficiary under the TRICARE program and a veteran for such selected drug, as established under the Social Security Act, and the maximum price of a selected drug procured by Federal agencies, and for other purposes. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES May 7, 2026 Mr. Vindman (for himself, Mr. Ryan, Ms. Houlahan, Mr. Keating, Ms. Goodlander, Mr. Deluzio, and Mr. Moulton) introduced the following bill; which was referred to the Committee on Veterans' Affairs, and in addition to the Committee on Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned _______________________________________________________________________ A BILL To amend titles 10 and 38, United States Code, to set the maximum cost- sharing amount paid by an eligible covered beneficiary under the TRICARE program and a veteran for such selected drug, as established under the Social Security Act, and the maximum price of a selected drug procured by Federal agencies, and for other purposes. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Maximizing Individual Savings for Servicemembers In Obtaining Negotiated Rx Act'' or the ``MISSION Rx Act''. SEC. 2. MAXIMUM PRICE FOR A SELECTED DRUG FOR THE COST-SHARING AMOUNT PAID BY AN ELIGIBLE COVERED BENEFICIARY UNDER TRICARE AND A VETERAN AND FOR FEDERAL PROCUREMENT. (a) Pharmacy Benefits Program.--Section 1074g of title 10, United States Code, is amended-- (1) in subsection (a)(6), by adding at the end the following new subparagraphs: ``(F) Notwithstanding subparagraphs (A), (B), and (C), during any year a selected drug is covered under the Drug Price Negotiation Program established under section 1191 of the Social Security Act (42 U.S.C. 1320f), the cost-sharing amount under this subsection during a year for such selected drug for an eligible covered beneficiary may not exceed the cost-sharing amount paid by a Medicare beneficiary for such selected drug in that year under part D of title XVIII of that Act (42 U.S.C. 1395w-101 et seq.) pursuant to such Drug Price Negotiation Program.''; and (2) in subsection (i), by adding at the end the following new paragraph: ``(5) The term `selected drug' has the meaning given such term in section 1192(c) of the Social Security Act (42 U.S.C. 1320f-1(c)).''. (b) Copayment for Medications.--Section 1722A of title 38, United States Code, is amended by adding at the end the following new subsections: ``(d) Notwithstanding subsections (a) and (b), during any year a selected drug is covered under the Drug Price Negotiation Program established under section 1191 of the Social Security Act (42 U.S.C. 1320f), the copayment amount determined under this section during a year for such selected drug for a veteran may not exceed the copayment amount paid by a Medicare beneficiary for such selected drug in that year under part D of title XVIII of that Act (42 U.S.C. 1395w-101 et seq.) pursuant to such Drug Price Negotiation Program. ``(e) In this section, the term `selected drug' has the meaning given such term in section 1192(c) of the Social Security Act (42 U.S.C. 1320f-1(c)).''. (c) Limitation on Prices of Drugs Procured by Department and Certain Other Federal Agencies.--Section 8126 of title 38, United States Code, is amended-- (1) in subsection (a)--…
Show the remaining 453 wordsHide the remaining 453 words
(A) in paragraph (3), by striking ``; and'' and inserting a semicolon; (B) in paragraph (4)(C), by striking the period and inserting ``; and''; and (C) by adding at the end the following new paragraph: ``(5) with respect to each selected drug of the manufacturer procured by a Federal agency, as described in subsection (b), such master agreement shall be subject to the requirements in subsection (j).''. (2) in subsection (g)(1), by striking ``1992'' and inserting ``1992, except with respect to any reference to a provision of such Act in paragraphs (7) and (8) of subsection (h) and in subsection (j)''; (3) in subsection (h)-- (A) by redesignating paragraphs (5) and (6) as paragraphs (6) and (8), respectively; (B) by inserting after paragraph (4) the following new paragraph: ``(5) The term `maximum fair price' has the meaning given such term in section 1191(c)(3) of the Social Security Act (42 U.S.C. 1320f(c)(3)).''; and (C) by inserting after paragraph (6), as redesignated by subparagraph (A), the following new paragraph: ``(7) The term `selected drug' has the meaning given such term in section 1192(c) of the Social Security Act (42 U.S.C. 1320f-1(c)).''; and (4) by adding at the end the following new subsections: ``(j) During any year a selected drug is covered under the Drug Price Negotiation Program established under section 1191 of the Social Security Act (42 U.S.C. 1320f), each manufacturer entering into a master agreement may not set the maximum price for such selected drug included in such master agreement at the time such master agreement is executed at a price exceeding the maximum fair price for such drug as set by such Drug Price Negotiation Program for the duration of such master agreement.''. (d) Application.-- (1) In general.--The amendments made in subsection (c) shall apply with respect to each master agreement under section 8126 of title 38, United States Code, covering a selected drug, as defined by such section, that is in effect on the date of the enactment of this Act or enters into force on or after such date. (2) Termination of the drug price negotiation program.-- Upon termination of the Drug Price Negotiation Program established under section 1191 of the Social Security Act (42 U.S.C. 1320f), each master agreement described in paragraph (1) shall be modified to reflect the drug price maximums as of the date of such modification under existing law for each selected drug, as defined in section 8126 of title 38, United States Code, as amended by subsection (c). (e) Conforming Amendments.--Part E of the Social Security Act (42 U.S.C. 1320f et seq.) is amended-- (1) in section 1193(a)(4)(A), by striking ``8126(h)(5)'' and inserting ``8126(h)''; and (2) in section 1194(c)(6), by striking ``8126(h)(5)'' and inserting ``8126(h)''. <all>
Open clean-text viewRead on Congress.gov →

Related legislation

Bills by the same sponsor or covering overlapping subjects.

  • HR9533Veterans Health Administration Personnel Transparency and Accountability Act
    Referred to Committee · 2026-06-29
  • HR9379Affordable Homes for Veterans Act of 2026
    Referred to Committee · 2026-06-18
  • HR9378Grocery Affordability Act
    Referred to Committee · 2026-06-18
  • HR9082Honesty and Trust in Service Act
    Referred to Committee · 2026-05-29